PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcneulBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Neurology
 
BMC Neurol. 2007; 7: 38.
Published online 2007 November 5. doi:  10.1186/1471-2377-7-38
PMCID: PMC2200655
Brain type carnosinase in dementia: a pilot study
Cynthia M Balion,corresponding author1,2 Carolyn Benson,1,2 Parminder S Raina,4 Alexandra Papaioannou,1,3 Christopher Patterson,1,3 and Afisi S Ismaila4
1Department of Laboratory Medicine, Hamilton Health Sciences, Hamilton, Ontario, Canada
2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
3Department of Medicine, McMaster University, Hamilton, Ontario, Canada
4Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada
corresponding authorCorresponding author.
Cynthia M Balion: balion/at/hhsc.ca; Carolyn Benson: cbenson2008/at/meds.uwo.ca; Parminder S Raina: praina/at/mcmaster.ca; Alexandra Papaioannou: Papaioannou/at/hhsc.ca; Christopher Patterson: pattec/at/hhsc.ca; Afisi S Ismaila: ismailas/at/mcmaster.ca
Received October 20, 2006; Accepted November 5, 2007.
Abstract
Background
The pathological processes underlying dementia are poorly understood and so are the markers which identify them. Carnosinase is a dipeptidase found almost exclusively in brain and serum. Carnosinase and its substrate carnosine have been linked to neuropathophysiological processes.
Methods
Carnosinase activity was measured by a flourometric method in 37 patients attending a Geriatric Outpatient Clinic. There were 17 patients without dementia, 13 had Alzheimer's disease (AD) and 7 had mixed dementia (MD).
Results
The range of serum carnosinase activity for patients without dementia was 14.5 – 78.5 μmol/ml/h. There was no difference in carnosinase activity between patients without dementia (40.3 ± 15.2 μmol/ml/h) and patients with AD (44.4 ± 12.4 μmol/ml/h) or MD (26.6 ± 15 μmol/ml/h). However, levels in the MD group were significantly lower than the AD group (p = 0.01). This difference remained significant after adjusting for gender, MMSE score, exercise, but not age, one at a time and all combined. The effect of other medical conditions did not remove the significance between the AD and MD groups. The MD group, but not the AD group, demonstrated a significant trend with carnosinase activity decreasing with duration of disease (from first recorded date of diagnosis to date of blood collection) (r = -0.76, p = 0.049). There was no association with carnosinase activity and MMSE score in the AD or MD group. Both AD and MD patients on any dementia medication (donepezil, galantamine, memantine) had higher carnosinase activity compared to those not taking a dementia medication. Carnosinase activity was higher in patients who regularly exercised (n = 20) compared to those who did not exercise regularly (n = 17)(p = 0.006).
Conclusion
This exploratory study has shown altered activities of the enzyme carnosinase in patients with dementia.
Articles from BMC Neurology are provided here courtesy of
BioMed Central